Attorney Docket No. 5739.200-US Weibel et al. Serial No. 09/450,609 Filed November 30, 1999 RECEIVED CENTRAL FAX CENTER

Attorney Docket No.: 5730.200-US

FEB 0 3 2005

**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.

Confirmation No.: 7926

Application No.: 09/450,609

Group Art Unit: 1617

Filed: November 30, 1999

Examiner: Kim, Jennifer M.

For: New Pharmaceutical Composition and the Process for Its Preparation

### PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the time for response to the non-final Office Action on the merits mailed August 3, 2004, having a shortened statutory period for reply set to expire November 3, 2004, subject to extensions of time under the provisions of 37 CFR §1.136(a), be extended for a period of three (3) months from November 3, 2004 to February 3, 2005, to permit timely filing of the Response enclosed herewith.

In the event that an additional extension of time is required, Applicants hereby petition for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Attorney Docket No. 5739.200-US Weibel et al. Serial No. 09/450,609 Filed November 30, 1999

Please charge the required fee, estimated to be \$1020, with this petition and credit any overpayments to Novo Nordisk Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 3, 2005

Rosemarie R. Wilk-Orescan, Reg. No. 45,220

Novo Nordisk Inc. 100 College Road West Princeton, NJ 08540 (609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE

# RECEIVED CENTRAL FAX CENTER

Attorney Docket No. 5739.200-US Weibel et al. Serial No. 09/450,609 Filed November 30, 1999 FEB 0 3 2005

Attorney Docket No.: 5730.200-US

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.

Confirmation No.: 7926

Application No.: 09/450,609

Group Art Unit: 1617

Filed: November 30, 1999

Examiner: Kim, Jennifer M.

For: New Pharmaceutical Composition and the Process for Its Preparation

## PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the time for response to the non-final Office Action on the merits mailed August 3, 2004, having a shortened statutory period for reply set to expire November 3, 2004, subject to extensions of time under the provisions of 37 CFR §1.136(a), be extended for a period of three (3) months from November 3, 2004 to February 3, 2005, to permit timely filing of the Response enclosed herewith.

In the event that an additional extension of time is required, Applicants hereby petition for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

02/03/2005 10:53 FAX 609 919 7741

Attorney Docket No. 5739.200-US Weibel et al. Serial No. 09/450,609 Filed November 30, 1999

Please charge the required fee, estimated to be \$1020, with this petition and credit any overpayments to Novo Nordisk Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 3, 2005

Rosemarie R. Wilk-Orescan, Reg. No. 45,220

Novo Nordisk Inc. 100 College Road West Princeton, NJ 08540 (609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650 PATENT TRADEMARK OFFICE